A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery.
Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around $2.9 billion).